SGO Annual Meeting on Women's Cancer

Intravenous and Direct-to-Abdomen Chemotherapy Plus Avastin Lead to Similar Outcomes in Advanced Ovarian Cancer

March 23rd 2022

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

Treatment With Novel Drug Induces Promising Response Rates in Ovarian Cancer Subgroup

March 22nd 2022

“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.

Zejula-Avastin Combo Improves Outcomes, With ‘No Impact on Quality of Life’ in High-Risk Ovarian Cancer

March 22nd 2022

Zejula plus Avastin led to promising progression-free survival rates with no new side effects for patients with newly diagnosed, advanced ovarian cancer.

Preventing Opioid Addiction in Patients With Cancer

March 28th 2018

Jaron Mark, M.D., a gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses the opioid crisis, and the steps that his institution is taking to combat potential addiction in women who undergo surgery for gynecologic cancer.

Ask an Expert: How Do PARP Inhibitors Work?

March 27th 2018

PARP inhibitors are generating a lot of excitement in the field of ovarian cancer. But how, exactly, do they work? CURE spoke with one expert to find out.

Gene Testing Can Help Improve Ovarian Cancer Care and Decision Making

March 26th 2018

Knowing which kind of therapy works best can help in determining the ideal cancer care for patients.

Checkpoint Inhibitors Induce Response, Higher Rates of Side Effects

March 26th 2018

“There has been a rapid expansion in the use of checkpoint inhibition in many solid tumor types,” lead author Emily Hinchcliff, M.D.

Four Individuals Named Ovarian Cancer Heroes at Inaugural Event

March 24th 2018

At the inaugural Ovarian Cancer Heroes gala, held in New Orleans ahead of the 49th Society of Gynecologic Oncology Annual Meeting on Women’s Cancers, four individuals — a physician, nurse navigator and two patient-turned-advocates — were awarded for the contributions they have made to increase awareness and advance research and education for ovarian cancer.

Lynparza Improves Progression-Free Survival in BRCA+ Ovarian Cancer

March 15th 2017

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improving Survival in BRCA-Proficient Ovarian Cancer

March 15th 2017

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.

Jubilee Brown on Genetic Counseling for Patients With Breast and Ovarian Cancer

March 15th 2017

Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

PARP Inhibitors Are Changing the Treatment Landscape for Ovarian Cancer

March 15th 2017

PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.

Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

March 15th 2017

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Niraparib Improves Progression-Free Survival in Ovarian Cancer, Regardless of BRCA Status

March 14th 2017

The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.

Declining Concern about HPV Vaccine and Sexual Activity

March 13th 2017

Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.

Genetic Counseling and Ovarian Cancer: 4 Questions With an Expert

March 13th 2017

Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.

Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer

March 13th 2017

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Rucaparib Shows Promising Activity in Recurrent Ovarian Cancer

March 13th 2017

Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.

Elizabeth Swisher Discusses Rucaparib's Side Effects for Patients With Ovarian Cancer

March 13th 2017

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.